Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02337270
Other study ID # M002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 5, 2017
Est. completion date September 7, 2021

Study information

Verified date October 2021
Source McMaster University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1 study, in healthy volunteers who have previously been immunized with bacilli Calmette Guerin (BCG), to evaluate the safety and immune responses that develop in the blood and lungs following the administration by aerosol of a new experimental adenovirus-based vaccine for tuberculosis (TB), Ad5Ag85A.


Description:

This is a phase 1, open label study to evaluate the safety and immunogenicity of a single administration of one of two doses of a recombinant replication deficient human adenoviral (Ad5) TB vaccine containing the immunodominant antigen Ag85A delivered to the respiratory tract by aerosol in healthy volunteers with a history of BCG immunization. 28 healthy volunteers will be enrolled. The first cohort (n=8) will receive a lower dose of vaccine using the AeroNeb Solo Vibrating Mesh Nebulizer. For the second cohort (n=20) participants will be randomized to either a higher dose of vaccine by aerosol (n=10) or intramuscular administration (n=10). Cellular immune responses in the lung and peripheral blood will be evaluated


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date September 7, 2021
Est. primary completion date September 7, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy human subjects who are between 18 and 55 years of age with a history of BCG vaccination. 2. HIV antibody negative 3. Able to understand and comply with protocol requirements and instructions; able to attend scheduled study visits and complete required investigations. 4. For women, negative pregnancy test and practicing two acceptable forms of contraception for the duration of the study (barrier contraceptive, birth control pill, surgically sterile, post-menopausal 2 years, abstinence) 5. For men, using barrier contraception for the duration of the study Exclusion Criteria: 1. Pregnant or lactating women 2. Subjects who have any acute or chronic illnesses including active tuberculosis, any relevant findings on physical examination or are receiving any drug treatment in the opinion of the investigator likely to affect the immune system including current use of inhaled or nasal steroids. 3. Subjects with a history of any bleeding disorder or receiving any drug treatment that in the opinion of the investigator may increase the risk of bleeding 4. Subjects with a history of respiratory disease, e.g. asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD). 5. Current smokers, including e-cigarettes, and ex-smokers who have quit within the last year, as reported by the subject 6. Subjects with clinically significant abnormality of baseline spirometry tests 7. Any health-related condition for which study bronchoscopy is contraindicated 8. Subjects who have a history of active or latent TB infection or whose PBMC's are responsive to ESAT6/CFP10 stimulation using a commercial interferon gamma release assay for TB [consistent with latent TB infection]. 9. Subjects whose baseline laboratory values are outside of the normal range unless the abnormality is considered not to be of clinical relevance by the Investigator. A single repeat test is allowed during the screening period. 10. Subjects whose use of alcohol or drugs would, in the opinion of the investigator, interfere with adherence to the study protocol. 11. Subjects who are using, or have a history of using, inhaled cocaine, metamphetamine or other inhaled or smoked recreational drugs. Subjects who give a history of last smoking marijuana more than a year ago may be enrolled, as long as they do not smoke marijuana for the duration of the study. 12. Failure to provide written consent. 13. Known allergy to vaccine components 14. Previous vaccination with Ad5Ag85A or any other experimental TB vaccine 15. Known exposure to active TB within past 6 months or subjects whose occupation puts them at increased risk of TB exposure (based on Hamilton Health Science/St Joseph Healthcare list of high risk personnel) 16. Any abnormality on chest x-ray suggestive of active or remote tuberculosis infection or evidence on chest-x-ray of clinically significant respiratory disease. 17. PPD skin test within last 12 months

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Ad5Ag85A
Aerosol administration of Ad5Ag85A

Locations

Country Name City State
Canada McMaster University Medical Centre Hamilton Ontario

Sponsors (2)

Lead Sponsor Collaborator
McMaster University Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants reporting adverse events Adverse events will be assessed according to the CTCAE Expanded Common Toxicity Criteria at 48-72 hours after vaccination, and at weeks 2, 4, 8, 12, 16 and 24 Over 24 weeks
Secondary Immunogenicity of one of two doses of Ad5Ag85A administered by aerosol Change from baseline in the immune responses of specific T-cells in bronchoalveolar lavage [BAL] fluid (mucosal) and blood (systemic). Immune responses measured will include interferon Elispot assay, cytokine production and intracellular cytokine staining Two weeks after vaccination
Secondary Immunogenicity of one of two doses of Ad5Ag85A administered by aerosol Eight (first cohort) or twelve (second cohort) weeks after vaccination
Secondary Immunogenicity of inhaled administration of Ad5Ag85A compared with intramuscular administration Two weeks after vaccination
Secondary Immunogenicity of inhaled administration of Ad5Ag85A compared with intramuscular administration Twelve weeks after vaccination
Secondary Number of participants reporting adverse events with inhaled administration of Ad5Ag85A compared with intramuscular administration Over 24 weeks
Secondary Immune responses measured from induced sputum compared with bronchoalveolar lavage For first cohort of 8 participants only Two weeks after vaccination
Secondary immune responses measured from induced sputum compared with bronchoalveolar lavage For first cohort of 8 participants only Eight weeks after vaccination
Secondary Number of participants developing a positive interferon release assay for TB after vaccination with Ad5Ag85A For first cohort of 8 patients only At 16 weeks
Secondary Number of participants reporting adverse events correlated with level of pre-existing anti-adenoviral antibodies Over 24 weeks
Secondary Immune response to vaccination correlated with pre-existing anti-adenoviral antibodies Two weeks after vaccination
Secondary Immune response to vaccination correlated with pre-existing anti-adenoviral antibodies Eight weeks after vaccination
Secondary Number of participants reporting adverse effects correlated with dose of vaccine received by inhalation Over 24 weeks
Secondary Immune response to vaccine correlated with dose of vaccine received by inhalation Two weeks after vaccination
Secondary Immune response to vaccine correlated with dose of vaccine received by inhalation Eight or 12 weeks after vaccination
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A